An observational study in Endometriosis, Adhesive, sponsored by Nordic Pharma SAS. Status unknown at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-01.
Sponsored by Nordic Pharma SAS · Observational
Thus is a longitudinal, prospective, multicentric observational study performed in mainland France, among a sample of gynaecology surgeons practising at endometriosis "expert" centres.
The aim of this study is to describe, under real treatment conditions in patients suffering from endometriosis, the impact of the use of anti-adhesion treatment during celioscopy surgery on the development of clinical signs in the patients and their fertility at one year.
901 studies on the registry are indexed under Endometriosis; 259 are open to participants now.
This study's enrollment of 364 is above the median of 128 across 344 observational studies indexed under Endometriosis.
Browse Endometriosis studies →Nordic Pharma SAS is the lead sponsor of 10 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subsequent patients of procreation age having undergone a cœlioscopy for endometriosis, for whom a spontaneous pregnancy is possible, whether or not they wish to become pregnant immediately, and meeting all of the selection criteria will be included in the study.
Exclusion Criteria:
Change on the clinical signs
The clinical change will be established after one year via the pain symptomatology reported by the patient, the rate of relapse (re-hospitalisation) and the rate of any eventual complications from the celioscopy (adhesions, etc.).
Time frame: At 2 months and one year after the baseline visit (i.e. celioscopy)
Fertility
rate of pregnancy women
Time frame: One year after the baseline visit (i.e. celioscopy)
This study is status unknown, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nordic Pharma SAS